Tesamorelin (off-label)Hormone analogue · use context
Tesamorelin stimulates the body’s growth-hormone pathway. Its best-known clinical research concerns excess abdominal visceral fat in people with HIV, a specific setting that cannot simply be expanded to general weight loss.
Before comparing this entry. The source separates a compounding or use context from the underlying substance. This is not a separate approval.
What is Tesamorelin (off-label)?
Compounded tesamorelin refers to a preparation of tesamorelin supplied through compounding. The term describes the preparation, not a new molecule or an independently established indication.
How it works
Tesamorelin mimics growth hormone-releasing hormone, prompting pituitary growth-hormone release and altering downstream IGF-1 signalling.
Effects studied
Visceral fat in HIV-associated fat accumulation
The US-approved medicine reduces excess abdominal fat in adults with HIV-associated lipodystrophy. It is not indicated for weight loss, and its long-term cardiovascular safety has not been established. 1
Evidence: Evidence concerning manufactured preparations cannot establish equivalence of an individually compounded product.
Why researchers have also studied liver fat
Liver fat is another research question. A 12-month randomised trial enrolled 61 people with HIV and non-alcoholic fatty liver disease. Tesamorelin reduced liver fat compared with placebo, providing a clinical signal in this specific population. Whether it improves long-term liver outcomes needs further study; this result does not establish a general fatty-liver indication or a benefit in otherwise healthy people. The study does not establish that a compounded preparation has the same composition or effect. 4
Evidence: Small randomised trial in HIV-associated fatty liver disease; liver fat is not a long-term clinical outcome.
What does the evidence show?
Trials in HIV-related abdominal fat; extrapolation to wellness use
What “compounded” means
Tesamorelin is an analogue of growth hormone-releasing hormone, the signal that prompts the pituitary gland to release growth hormone. This also changes downstream IGF-1 signalling. The “compounded” label describes how a preparation is supplied; it does not identify a new molecule or an independently proven use.
The fat compartment matters
The US-approved medicine reduces excess abdominal fat in adults with HIV-associated lipodystrophy. It is not indicated for weight loss, and its long-term cardiovascular safety has not been established. 1
These findings concern the tested medicine. They do not establish the quality or clinical equivalence of an individually compounded preparation.
What those trials leave open
The relevant comparison is the same population, preparation and outcome over time. A trial of a manufactured medicine cannot establish the quality or clinical equivalence of an individually compounded preparation. Nor can a change on an abdominal scan establish a durable benefit after treatment stops.
Why researchers have also studied liver fat
Liver fat is another research question. A 12-month randomised trial enrolled 61 people with HIV and non-alcoholic fatty liver disease. Tesamorelin reduced liver fat compared with placebo, providing a clinical signal in this specific population. Whether it improves long-term liver outcomes needs further study; this result does not establish a general fatty-liver indication or a benefit in otherwise healthy people. The study does not establish that a compounded preparation has the same composition or effect. 4
Why the hormone pathway needs monitoring
The US label contraindicates Egrifta WR during pregnancy, in active cancer, with disruption of the hypothalamic–pituitary axis, or with known hypersensitivity to tesamorelin or its ingredients. A treated, stable cancer history calls for a separate benefit–risk assessment; it is not the same as active cancer. 1
Glucose and IGF-1 need monitoring. Fluid retention, joint symptoms, injection reactions and hypersensitivity can occur. Egrifta WR and SV differ in preparation and dosing and are not substitutable. 1 3
Safety & status
The US label contraindicates Egrifta WR during pregnancy, in active cancer, with disruption of the hypothalamic–pituitary axis, or with known hypersensitivity to tesamorelin or its ingredients. A treated, stable cancer history calls for a separate benefit–risk assessment; it is not the same as active cancer. 1
Glucose and IGF-1 need monitoring. Fluid retention, joint symptoms, injection reactions and hypersensitivity can occur. Egrifta WR and SV differ in preparation and dosing and are not substitutable. 1 3
Country and product status
US Egrifta WR label reviewed; the cited EMA withdrawal dates to 2012. Current EU and Swiss availability requires a separate check.
Frequently asked questions
Is compounded tesamorelin a different peptide?
No. “Compounded” describes how the preparation is supplied, rather than a different active molecule.
Does less visceral fat mean weight loss for everyone?
No. Reducing visceral fat in HIV-associated lipodystrophy does not establish a general weight-loss benefit. 1
Further reading
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- DailyMed: Egrifta WR prescribing information US prescribing information · Indication, limitations, contraindications and warnings; checked 2026-10-29
- EMA: Egrifta application withdrawn in 2012 EU regulator · Historical withdrawal information; not an exhaustive current authorisation search; checked 2026-10-29
- Egrifta WR prescribing information: WR and SV are not substitutable Manufacturer prescribing information · Formulation warning; checked 2026-10-29
- Stanley et al. (2019): Effects of tesamorelin on non-alcoholic fatty liver disease in HIV Randomised controlled trial · PubMed abstract; full paper not reviewed; checked 2026-10-29
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.